Zenith Therapeutics aims to exploit native protein interactions to drug previously undruggable oncology targets. Their platform harnesses physiological quality control mechanism to modulate transcription factors (TF) by identifying native and privileged TF/E3-ligase pairs. Through the discovery of small molecules that impact pairs with existing affinity, Zenith is developing novel TF modulators for the treatment of disease.